David E.I. Pyott, who serves as a director at Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), sold common stock valued at approximately $1.15 million on June 1, 2026. The disposition of shares occurred at prices ranging between $297.71 and $302.65 per share.
This reported activity comes as the current trading price for ALNY stands at $292.58. This level is close to the stock's 52-week low of $284.28, representing a significant decline from its 52-week high of $495.55. Over the past six months, the shares have experienced an approximate 40% decrease in value.
Details of the Transaction
The specific sale involved the liquidation of 3,830 shares of Alnylam common stock. These particular shares were acquired on the same day through the exercise of existing stock options. The transaction was linked to options that had an original exercise price of $70.20 per share and were fully vested as of June 3, 2017.
Crucially, these sales were executed under the framework of a Rule 10b5-1(c) trading plan. Mr. Pyott adopted this prearranged plan on November 12, 2025.
Following the recent sale, Mr. Pyott maintains direct ownership of 1,582 shares of Alnylam common stock. Furthermore, an additional holding of 27,900 shares of ALNY common stock is held indirectly by the David E I Pyott Trust, where he acts as trustee.
In parallel corporate news, Alnylam Pharmaceuticals released financial data for the first quarter of 2026. The company reported a record revenue figure totaling $1.17 billion, which exceeded the analyst consensus forecast of $1.12 billion. Earnings per share also proved strong at $1.99, significantly surpassing the expected value of $0.91.
For the quarter, total net product revenue reached $1,036 million. This figure represents a substantial 121% increase compared to the previous year, although it fell slightly short of the firm’s internal estimate of $1,071 million.
Industry analysts have provided varied commentary on these results. H.C. Wainwright maintained a Buy rating and set a price target of $510, citing strong TTR sales as a positive contributor to the company's performance. Meanwhile, Bernstein SocGen Group adjusted its price target down from $448 to $447 but nonetheless upheld an Outperform rating. This group also noted that Amvuttra sales surpassed consensus estimates by 5%, though they concurrently raised concerns regarding the degree of reliance on sales generated outside the United States.
Overall, these developments illustrate Alnylam’s continued trajectory of growth and its strong market execution. The financial reporting highlights both significant achievements in revenue generation and earnings performance while also detailing specific areas of concern for analysts to consider.
Risks
- The stock has declined approximately 40% over the last six months and trades near its 52-week low.
- Bernstein SocGen Group expressed concern regarding the company's reliance on sales outside of the United States.
- Total net product revenue was slightly below the firm’s estimate of $1,071 million.
More from Insider Trading